Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ERYP.PA (Common Stock)
ExchangeParis (Euro)
Price€21.27
Change (%) Stock is Up 0.21 (1.00%)
Volume18,624
Data as of 08/30/16 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
30-Aug-2016ERYTECH to Hold Q2 2016 Business Update Conference Call on September 7th, 2016
LYON, France--(BUSINESS WIRE)--Aug. 30, 2016-- Regulatory News: ERYTECH (Euronext Paris: FR0011471135 - ERYP) (Paris:ERYP) (ADR:EYRYY), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it will release its financial results and business update for the quarter ended June 30, 2016 on Tuesday, September 06, 2... 
 Printer Friendly Version
29-Aug-2016ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia
Primary data read-out for the European trial expected in 2H2017 LYON, France--(BUSINESS WIRE)--Aug. 29, 2016-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it has reached full patient enrollment in the Phase 2b trial of eryaspas... 
 Printer Friendly Version
02-Aug-2016Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - July 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Aug. 2, 2016-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
11-Jul-2016Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - June 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jul. 11, 2016-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
09/06/16
Second Quarter and Half-Year 2016 Financial Results and Business Update: press release on Tuesday, September 6, 2016, (after market)
09/07/16 3:00 p.m. CET
Second Quarter and Half-Year 2016 Financial Results and Business Update: Conference Call
11/03/16
Third Quarter 2016 Financial Results and Business Update: press release on Thursday, November 3, 2016, (after market)
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top